HHS to Create New Potential Medicare Pricing Models for Cell and Gene Therapy, Drugs Subject to Accelerated FDA Approval, and High-Value Generics | Goodwin

On February 14, 2023, the U.S. Department of Health and Human Services (HHS) published a report identifying three models that the Center for Medicare & Medicaid Services’ (CMS) Center...

Related Keywords

United States ,Americans ,America , ,Health Human Serv ,Us Department Of Health ,Human Services ,Access Commission ,Medicare Medicaid Service ,Advisory Commission Med ,Approval Program ,Medicaid Drug Rebate Program ,Medicaid Service ,Medicaid Innovation ,Inflation Reduction Act ,President Biden ,Executive Order ,Models Selected ,Medicare High Value Generic Drug List ,Medicare High Value Drug List Model ,Partd Senior Savings Model ,Gene Therapy Access ,Gene Therapy Access Model ,Medicaid Drug Rebate ,Accelerating Clinical Evidence ,Accelerated Approval Pathway ,Accelerating Clinical Evidence Model ,Medicare Payment ,Advisory Commission ,Advance Notice ,Proposed Rulemaking ,Human Serv ,Lowering Prescription Drug Costs ,Drug Admin ,Accelerated Approval Program ,